JP2020519643A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519643A5
JP2020519643A5 JP2019562565A JP2019562565A JP2020519643A5 JP 2020519643 A5 JP2020519643 A5 JP 2020519643A5 JP 2019562565 A JP2019562565 A JP 2019562565A JP 2019562565 A JP2019562565 A JP 2019562565A JP 2020519643 A5 JP2020519643 A5 JP 2020519643A5
Authority
JP
Japan
Prior art keywords
msln
seq
domain
amino acid
protein according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019562565A
Other languages
English (en)
Japanese (ja)
Other versions
JP7209936B2 (ja
JP2020519643A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/032427 external-priority patent/WO2018209304A1/en
Publication of JP2020519643A publication Critical patent/JP2020519643A/ja
Publication of JP2020519643A5 publication Critical patent/JP2020519643A5/ja
Priority to JP2022202550A priority Critical patent/JP2023103173A/ja
Application granted granted Critical
Publication of JP7209936B2 publication Critical patent/JP7209936B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019562565A 2017-05-12 2018-05-11 Msln標的三重特異性タンパク質及びその使用方法 Active JP7209936B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022202550A JP2023103173A (ja) 2017-05-12 2022-12-19 Msln標的三重特異性タンパク質及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762505747P 2017-05-12 2017-05-12
US62/505,747 2017-05-12
US201862657434P 2018-04-13 2018-04-13
US62/657,434 2018-04-13
PCT/US2018/032427 WO2018209304A1 (en) 2017-05-12 2018-05-11 Msln targeting trispecific proteins and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022202550A Division JP2023103173A (ja) 2017-05-12 2022-12-19 Msln標的三重特異性タンパク質及びその使用方法

Publications (3)

Publication Number Publication Date
JP2020519643A JP2020519643A (ja) 2020-07-02
JP2020519643A5 true JP2020519643A5 (enExample) 2021-07-26
JP7209936B2 JP7209936B2 (ja) 2023-01-23

Family

ID=64095980

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019562565A Active JP7209936B2 (ja) 2017-05-12 2018-05-11 Msln標的三重特異性タンパク質及びその使用方法
JP2022202550A Pending JP2023103173A (ja) 2017-05-12 2022-12-19 Msln標的三重特異性タンパク質及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022202550A Pending JP2023103173A (ja) 2017-05-12 2022-12-19 Msln標的三重特異性タンパク質及びその使用方法

Country Status (9)

Country Link
US (1) US10730954B2 (enExample)
EP (1) EP3621648A4 (enExample)
JP (2) JP7209936B2 (enExample)
KR (1) KR20200026810A (enExample)
CN (2) CN115028727A (enExample)
AU (1) AU2018265860B2 (enExample)
BR (1) BR112019023856A2 (enExample)
CA (1) CA3063362A1 (enExample)
WO (1) WO2018209304A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
HRP20191865T1 (hr) 2013-01-14 2020-01-10 Xencor, Inc. Novi heterodimerni proteini
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
CN116333153A (zh) 2014-11-26 2023-06-27 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
CN111234027A (zh) 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN109641046B (zh) 2016-05-20 2023-11-07 哈普恩治疗公司 单链可变片段cd3结合蛋白质
BR112018073739A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteína de ligação de albumina sérica de domínio único
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
IL302917A (en) 2016-10-07 2023-07-01 Tcr2 Therapeutics Inc Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP6812551B2 (ja) 2016-11-23 2021-01-13 ハープーン セラピューティクス,インク. 前立腺特異的膜抗原結合タンパク質
JP7215997B2 (ja) 2016-11-23 2023-01-31 ハープーン セラピューティクス,インク. 前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CA3063362A1 (en) * 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
US20200270362A1 (en) * 2017-05-12 2020-08-27 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
UA129446C2 (uk) 2017-10-13 2025-04-30 Гарпун Терап'Ютікс, Інк. Триспецифічні білки і способи їх застосування
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
WO2019222283A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
IL295448A (en) 2020-02-21 2022-10-01 Harpoon Therapeutics Inc flt3 binding proteins and methods of use
US20220106403A1 (en) * 2020-05-14 2022-04-07 Xencor, Inc. Heterodimeric antibodies that bind msln and cd3
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
US20240034806A1 (en) * 2020-12-09 2024-02-01 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
MX2023006817A (es) * 2020-12-09 2023-08-14 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Cd3及びcldn6に結合するヘテロ二量体抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Cd3及びgpc3に結合するヘテロ二量体抗体
TW202321296A (zh) 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
CN118660911A (zh) * 2021-12-10 2024-09-17 默沙东有限责任公司 人间皮素结合剂
EP4458861A1 (en) * 2021-12-29 2024-11-06 Sichuan Huiyu Pharmaceutical Co., Ltd. Antibody targeting cd3, multispecific antibody, and uses thereof
CN118139892A (zh) * 2022-01-14 2024-06-04 浙江道尔生物科技有限公司 一种三靶点抗肿瘤药物、其制备方法及其应用
WO2023153711A1 (ko) * 2022-02-10 2023-08-17 경북대학교 산학협력단 메소세린에 결합하는 펩타이드 및 이의 용도
WO2023164627A1 (en) 2022-02-24 2023-08-31 Xencor, Inc. Anti-cd28 x anti-msln antibodies
EP4490192A1 (en) 2022-03-07 2025-01-15 Novimmune S.A. Cd28 bispecific antibodies for targeted t cell activation
US12122850B2 (en) 2022-03-14 2024-10-22 LamKap Bio gamma AG Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
AU2023240941A1 (en) * 2022-03-25 2024-09-19 Shanghai Henlius Biologics Co., Ltd. Anti-msln antibodies and methods of use
JP2025526442A (ja) 2022-07-29 2025-08-13 ザイムワークス ビーシー インコーポレイテッド 多価かつ二重特異性の抗体構築物およびその使用方法
JP2025002813A (ja) 2023-06-23 2025-01-09 セイコーエプソン株式会社 シート製造装置
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025082777A1 (en) * 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025132770A1 (en) * 2023-12-22 2025-06-26 Institut National de la Santé et de la Recherche Médicale Affitins for the treatment of cancer
WO2025163144A1 (en) * 2024-01-31 2025-08-07 Molecular Partners Ag Recombinant mesothelin binding proteins and their use

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993007105A1 (en) 1991-10-04 1993-04-15 Iit Research Institute Conversion of plastic waste to useful oils
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
BR9813276A (pt) 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
WO2000043507A1 (en) 1999-01-19 2000-07-27 Unilever Plc Method for producing antibody fragments
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
DK1257632T3 (da) 2000-02-24 2008-01-28 Xcyte Therapies Inc Samtidig stimulering og opkoncentrering af celler
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
CN1195779C (zh) 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
ES2606537T3 (es) 2001-10-23 2017-03-24 Psma Development Company L.L.C. Anticuerpos contra PSMA
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
CN1652821A (zh) 2002-01-28 2005-08-10 米德列斯公司 抗前列腺特异性膜抗原(psma)的人单克隆抗体
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
CA2505515C (en) 2002-11-07 2013-08-27 Erasmus Universiteit Rotterdam Fret probes and methods for detecting interacting molecules
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN102584997A (zh) 2002-11-08 2012-07-18 埃博灵克斯股份有限公司 针对肿瘤坏死因子-α的单结构域抗体及其用途
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
CA2523716C (en) 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
KR20060041205A (ko) 2003-07-01 2006-05-11 이뮤노메딕스, 인코오포레이티드 양특이성 항체들의 다가 담체들
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
AU2004280333A1 (en) 2003-08-22 2005-04-21 Medimmune, Llc Humanization of antibodies
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
KR20120133403A (ko) 2004-06-01 2012-12-10 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
US20080069772A1 (en) 2004-08-26 2008-03-20 Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum Treatment of transformed or infected biological cells
EP1634603A1 (de) 2004-08-26 2006-03-15 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von transformierten oder infizierten biologischen Zellen
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
AU2006204459B2 (en) 2005-01-05 2012-11-01 F-Star Therapeutics Limited Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US20060252096A1 (en) 2005-04-26 2006-11-09 Glycofi, Inc. Single chain antibody with cleavable linker
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
CN101213214B (zh) 2005-05-20 2014-06-25 埃博灵克斯股份有限公司 针对冯威勒布兰特因子的单一结构域vhh抗体
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
TWI323734B (en) 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
ES2856451T3 (es) 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
JP5102772B2 (ja) 2005-11-29 2012-12-19 ザ・ユニバーシティ・オブ・シドニー デミボディ:二量体化活性化治療剤
WO2007115230A2 (en) 2006-03-30 2007-10-11 University Of Medicine And Dentistry Of New Jersey A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
KR101589759B1 (ko) 2007-04-03 2016-01-29 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 cd3―입실론 결합 도메인
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP3492488A1 (en) 2007-08-22 2019-06-05 The Regents of The University of California Activatable binding polypeptides and methods of identification and use thereof
WO2009030285A1 (en) 2007-09-07 2009-03-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
ES2667729T3 (es) 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
DK2285408T3 (en) * 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
US20110177070A1 (en) 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
EP2352763B2 (en) 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
CA2740561C (en) 2008-10-14 2021-01-19 National Research Council Of Canada Bsa-specific antibodies
EP2356131A4 (en) 2008-12-08 2012-09-12 Tegopharm Corp MASKING LIGANDS FOR REVERSIBLE INHIBITION OF VERSATILE COMPOUNDS
EP2210902A1 (en) 2009-01-14 2010-07-28 TcL Pharma Recombinant monovalent antibodies
PE20160653A1 (es) 2009-03-05 2016-07-24 Abbvie Inc Proteinas de union a il-17
UY32917A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック, インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
EP2332994A1 (en) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
EP2519544A1 (en) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
EP2550529B1 (en) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
WO2011117423A1 (en) * 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
RU2013110876A (ru) 2010-08-24 2014-09-27 Рош Гликарт Аг Активируемые биспецифические антитела
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
EP2640750A1 (en) 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents and methods for treating diseases that correlate with bcma expression
WO2012131053A1 (en) 2011-03-30 2012-10-04 Ablynx Nv Methods of treating immune disorders with single domain antibodies against tnf-alpha
CN107188969B (zh) 2011-04-08 2021-08-27 美国卫生和人力服务部 抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP2753644A1 (en) 2011-09-09 2014-07-16 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
US20150079093A1 (en) 2012-01-13 2015-03-19 Julus-Maximilians-Universität Würzburg Dual antigen-induced bipartite functional complementation
EP2807189B1 (en) 2012-01-23 2019-03-20 Ablynx N.V. Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
ES2812849T3 (es) 2012-02-24 2021-03-18 Abbvie Stemcentrx Llc Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20150037334A1 (en) 2012-03-01 2015-02-05 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
RU2014143639A (ru) 2012-03-30 2016-05-27 Байер Хелскеа Ллк Регулируемые протеазой антитела
CN104487587A (zh) 2012-04-20 2015-04-01 新兴产品开发西雅图有限公司 Cd3结合多肽
US9856314B2 (en) 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014033304A2 (en) 2012-08-31 2014-03-06 arGEN-X BV Highly diverse combinatorial antibody libraries
KR101963231B1 (ko) 2012-09-11 2019-03-28 삼성전자주식회사 이중특이 항체의 제작을 위한 단백질 복합체 및 이를 이용한 이중특이 항체 제조 방법
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
AU2013324049B2 (en) * 2012-09-27 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
JP6420776B2 (ja) 2013-03-05 2018-11-07 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 免疫療法のためのエンゲージャー細胞
CA2906587C (en) 2013-03-13 2023-02-14 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
US20160122436A1 (en) 2013-03-15 2016-05-05 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
US20140308285A1 (en) * 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
CA2918795A1 (en) 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
JP2016538327A (ja) 2013-09-24 2016-12-08 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション デスモグレイン2(dsg2)結合タンパク質およびその使用
AU2014326674B2 (en) 2013-09-26 2020-03-12 Ablynx Nv Bispecific nanobodies
ES2923641T3 (es) 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Inmunoglobulina con Fabs en tándem y usos de la misma
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
NZ726520A (en) 2014-05-29 2018-12-21 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
AR101400A1 (es) * 2014-07-31 2016-12-14 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
RS60305B1 (sr) 2014-09-05 2020-07-31 Janssen Pharmaceutica Nv Agensi koji vezuju cd123 i njihove upotrebe
CN105471609B (zh) 2014-09-05 2019-04-05 华为技术有限公司 一种用于配置业务的方法和装置
CA2960128A1 (en) 2014-09-25 2016-03-31 Amgen Inc Protease-activatable bispecific proteins
AU2015330017A1 (en) 2014-10-07 2017-04-27 Cellectis Method for modulating car-induced immune cells activity
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
JP6772157B2 (ja) 2015-02-05 2020-10-21 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. インフルエンザヘマグルチニンに対する結合分子及びその使用
CN114644689A (zh) 2015-04-22 2022-06-21 农业生物群落股份有限公司 杀虫基因和使用方法
HK1250997A1 (zh) 2015-05-01 2019-01-18 基因泰克公司 掩蔽抗cd3抗体和使用方法
CN111234027A (zh) * 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
WO2016187101A2 (en) 2015-05-21 2016-11-24 Full Spectrum Genetics, Inc. Method of improving characteristics of proteins
EP3960864A3 (en) 2015-06-03 2022-06-15 Agbiome, Inc. Pesticidal genes and methods of use
US10822419B2 (en) 2015-06-26 2020-11-03 University Of Southern California Masking chimeric antigen receptor T cells for tumor-specific activation
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究(慕尼黑)公司 Msln及cd3抗體構築體
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
WO2017025698A1 (en) 2015-08-11 2017-02-16 Queen Mary University Of London Bispecific, cleavable antibodies
CN106519037B (zh) 2015-09-11 2019-07-23 科济生物医药(上海)有限公司 可活化的嵌合受体
CA3004299A1 (en) 2015-11-05 2017-05-11 City Of Hope Methods for preparing cells for adoptive t cell therapy
AU2016358296B2 (en) 2015-11-19 2020-05-21 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CN108884126B (zh) 2016-02-03 2022-03-18 广州康睿生物医药科技股份有限公司 用于治疗眼睛病症或疾病的化合物
TW201808990A (zh) 2016-03-08 2018-03-16 馬弗瑞克療法公司 可誘導性結合蛋白和使用方法
CN109641046B (zh) 2016-05-20 2023-11-07 哈普恩治疗公司 单链可变片段cd3结合蛋白质
BR112018073739A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteína de ligação de albumina sérica de domínio único
IL302917A (en) * 2016-10-07 2023-07-01 Tcr2 Therapeutics Inc Compositions and methods for t-cell receptors reprogramming using fusion proteins
US20190225702A1 (en) 2016-10-14 2019-07-25 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
JP6812551B2 (ja) 2016-11-23 2021-01-13 ハープーン セラピューティクス,インク. 前立腺特異的膜抗原結合タンパク質
JP7215997B2 (ja) 2016-11-23 2023-01-31 ハープーン セラピューティクス,インク. 前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法
WO2018136725A1 (en) 2017-01-19 2018-07-26 Harpoon Therapeutics, Inc. Innate immune cell inducible binding proteins and methods of use
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018160671A1 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Targeted checkpoint inhibitors and methods of use
US20200115461A1 (en) 2017-05-03 2020-04-16 Harpoon Therapeutics, Inc. Compositions and methods for adoptive cell therapies
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
CA3063359A1 (en) * 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
UA129446C2 (uk) 2017-10-13 2025-04-30 Гарпун Терап'Ютікс, Інк. Триспецифічні білки і способи їх застосування
US20210284728A1 (en) 2018-05-14 2021-09-16 Harpoon Therapeutics, Inc. Dual binding moiety
WO2019222282A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
WO2019222283A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules

Similar Documents

Publication Publication Date Title
JP2020519643A5 (enExample)
JP2020537644A5 (enExample)
JP2019535763A5 (enExample)
JP2020536888A5 (enExample)
RU2505603C2 (ru) Антитело против рецептора il-6
JP2016536322A5 (enExample)
RU2363706C2 (ru) Антитела к рецептору инсулиноподобного фактора роста i и их применение
JP2025111463A5 (enExample)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
EA201991099A1 (ru) Антитела против cd73 и их применение
JP2017113028A5 (enExample)
JP2018517431A5 (enExample)
JP2020524675A5 (enExample)
JP2018172439A5 (enExample)
RU2015141428A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
JP2020506898A5 (enExample)
RU2006115835A (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2020501532A5 (enExample)
JP2017536341A5 (enExample)
JP2010521147A5 (enExample)
RU2015151505A (ru) Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1)
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
PE20071055A1 (es) Anticuerpos anti mn
WO2016207304A8 (en) Monoclonal anti-il-1racp antibodies
JP2024167313A5 (enExample)